Sign up to save your podcasts
Or
Share Applying Key Updates from ESC/HFA to Managing Heart Failure
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Applying Key Updates from ESC/HFA to Managing Heart Failure
CME credits: 0.25
Valid until: 23-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/applying-key-updates-esc-hfa-managing-heart-failure/13026/
Rapid initiation and up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is critical in the management of heart failure, especially given the prevalence of comorbid conditions, such as recurrent hyperkalemia, in these patients. To improve patient outcomes, it is crucial that physicians avoid any unnecessary halting or dose reductions to these medications.
In this discussion, Drs. Coats and Fonarow review updates to the ESC/HFA guidelines and explain how these changes affect patient care. Find out how to maintain optimal RAASi therapy for your patients with heart failure in the face of their challenging comorbidities.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 23-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/applying-key-updates-esc-hfa-managing-heart-failure/13026/
Rapid initiation and up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is critical in the management of heart failure, especially given the prevalence of comorbid conditions, such as recurrent hyperkalemia, in these patients. To improve patient outcomes, it is crucial that physicians avoid any unnecessary halting or dose reductions to these medications.
In this discussion, Drs. Coats and Fonarow review updates to the ESC/HFA guidelines and explain how these changes affect patient care. Find out how to maintain optimal RAASi therapy for your patients with heart failure in the face of their challenging comorbidities.